Open AccessClinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report
Author(s) -
Gang Shen,
Yinping Du,
Jifang Shen,
Junling Zhang,
Xihua Xia,
Mengli Huang,
Wenxiang Shen
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s340984
Subject(s) - alectinib , crizotinib , ceritinib , anaplastic lymphoma kinase , medicine , lung cancer , oncology , adenocarcinoma , alk inhibitor , adverse effect , cancer , malignant pleural effusion
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom